Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - BIO-PATH HOLDINGS INC | tm2019764d1_8k.htm |
Exhibit 99.1
Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting
HOUSTON—May 13, 2020 – Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming virtual poster presentation at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 29-31, 2020.
Dr. Maro Ohanian, Department of Leukemia, University of Texas M.D. Anderson Cancer Center, will discuss the Phase 2 study design of BP1001 (liposomal Grb2 antisense), the Company’s lead drug candidate, in combination with decitabine as a potential treatment for patients diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome.
Details for the virtual poster presentation are as follows:
Date: Friday, May 29, 2020
Presentation Time: 8:00 am Eastern Time
Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant
Abstract: TPS7561
Poster: 334
Title: A phase II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in patients with hematologic malignancies
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has
yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple
intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001,
targeting the Grb2 protein), is in a Phase 2 study for the treatment of blood cancers and has
filed an IND for a Phase 1 clinical trial for solid tumors. The Company’s second pipeline
candidate is BP1002, which targets the Bcl-2 protein and is planned to be evaluated for the
treatment of lymphoma and chronic lymphocytic leukemia. In addition, an IND application
for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide
developed by Bio-Path as a specific inhibitor of STAT3, is expected to be filed in 2020.
For more information, please visit the Company's website at
http://www.biopathholdings.com.
Contact Information:
Investors
Will O’Connor
Stern Investor Relations, Inc.
212-362-1200
will@sternir.com
Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369